Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Drug Testing: Principles and Biological Matrices in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The consensus document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    Michael M. Miller

    MD, LFAPA, DFASAM

    Michael M. Miller, MD, DFASAM, LFAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, Wisconsin. He is a board-certified general psychiatrist and addiction psychiatrist. Dr. Miller has practiced addiction medicine for more than 30 years and is certified in addiction medicine by the American Board of Addiction Medicine. He is a Life Fellow of the American Psychiatric Association (APA) and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation, as well as a past president of ASAM. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS), was chair of the WMS Commission on Addictive Diseases, and is current Speaker of the WMS House of Delegates and a member of the Society's Board of Directors. He serves as a faculty member for the Addiction Psychiatry Fellowship and the Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is a Clinical Adjunct Professor. He also is an assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. Dr. Miller was named the national physician Clinician of the Year by Addiction Professional magazine in 2011. He was the recipient of The ASAM Award in 2013.. Through 2015, he chaired the Steering Committee of ASAM's Practice Improvement and Performance Measurement Action Group. In June 2014, Dr. Miller was elected by the AMA House of Delegates to a four year term on the AMA Council on Science and Public Health.

    Learning Objectives: 
    -Describe the principles of drug testing in the assessment and monitoring of patients with, or at risk for, addiction 
    -Discuss the benefits and liabilities of the different biological matrices relative to their roles in drug testing 
    -Highlight the consensus document's recommendations and discuss their use in clinical practice

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Speaker Disclosure

    Name: Michael M. Miller, MD, DFASAM

    Nature of Relevant Financial Relationship

    Category

    Organization

    Type of Relationship

    Consultant

    World Meds

    Modest ($10,000 or less)

    Consultant

    BDSI

    Modest ($10,000 or less)

    Consultant

    Braeburn

    Modest ($10,000 or less)

    Consultant

    Purdue Pharma

    Modest ($10,000 or less)

    Consultant

    WPS

    Modest ($10,000 or less)

    Speaker/Speaker’s Bureau

    BDSI

    Modest ($10,000 or less)


    ASAM CME Committee and Reviewers Disclosure Listing

    NameCommercial InterestWhat was received?For what role?
    Catherine Friedman, MD, FAPA, FASAM, ChairNone  
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
    None   
    Noel Ilogu, MD, MRCP, DFASAMNone  
    Hebert L. Malinoff, MD, FACP, DFASAMNone  
    Edwin A. Salsitz, MD, DFASAMNone  
    John C. Tanner, DO, DABAM, DFASAM, CCFC, MROIndivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

  • Drug Testing: Special Populations and Additional Considerations in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today.

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    JoAn Laes

    MD

    JoAn Laes, MD, Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN; Consulting Medical Toxicologist, Minnesota Poison Control System, Minneapolis, MN; Medical Director, Mission Detox Center, Plymouth, MN

    Dr. Laes' practice is focused on inpatient addiction medicine and toxicology consultation and outpatient treatment of opioid and other substance use disorders.. She is board certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives

    • Identify the unique considerations in drug testing for special populations including adolescents and pregnant women. 
    • Summarize the consensus document's recommendations for drug testing for special populations and discuss how they should be used in practice.
    • Analyze the importance of practitioner documentation, confidentiality, language and attitude in addiction treatment.
    • Determine how to appropriately conduct drug testing on-site and/or choose a qualified laboratory.
  • Drug Testing: Process and Settings in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    image


    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. It will allow physicians to determine clearly how to choose and schedule a test, and respond to test results. It will also allow physicians to recognize the specific guidance warranted by different settings and levels of care including early intervention, outpatient services, intensive outpatient/partial hospitalization services, residential/inpatient care, medically management intensive inpatient services, and opioid treatment services. This webinar is intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population. 

    Ken Freedman

    MD, MS, MBA, DFASAM

    Since 2009, Dr. Freedman has worked as the Chief Medical Officer of Lemuel Shattuck Hospital in Boston; a facility that cares for many patients with substance use disorder, previously serving as Chief of Medicine. In addition, he is also a Clinical Professor of Medicine at Tufts University School of Medicine and Adjunct Clinical Associate Professor of Psychiatry at the University of Massachusetts Medical School. Dr. Freedman is board-certified in addiction medicine, internal medicine, and gastroenterology, and a member of the AMA, ACP, and AGA. He has been a member of ASAM since 1997.

    Over the past 20 years, Dr. Freedman has used his wide range of clinical and managerial skills to serve the needs of behavioral health and substance use patients. He teaches clinicians on the medically appropriate and humane treatment of pain disorders. Dr. Freedman’s professional commitment is to help move health care delivery towards the integration of medical care and substance use treatment in respectful and innovative ways. 

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives 
    1. Identify the fundamental components of the process of drug testing in addiction treatment. 
    2. Determine how to appropriately select the type of test for each patient, and how to respond to various test results. 
    3. Analyze the importance of and guidance around test scheduling and frequency. 
    4. Recognize the specific guidance warranted by drug testing in different settings and levels of care. 

  • The ASAM Review Course Spotlight Webinar Series (6 CME)

    Contains 24 Component(s), Medical Credits Offered

    This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine 2017.

    REVIEW COURSE ATTENDEES RECEIVE 25% OFF - 
    Use the promo code located in your syllabus when checking out to take advantage of this special deal!

    Looking to stay engaged and expand your ASAM Review Course experience? This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine. 

    Each webinar will be an hour long, with 30-45 minutes of lecture on the topic of the week and the rest saved for audience questions. Questions will be collected in advance from participants of the 2017 Review Course and as part of the webinar registration process – don’t miss your chance to ask the experts! 

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician at Mount Sinai Beth Israel, Department of Psychiatry and Behavioral Sciences, since 1983, and is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.  He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.  Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease.  He  lectures frequently and has been published on a variety of addiction medicine topics.

    Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT and PCSS-O mentoring programs. He has co-chaired  the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art Course and  is a reviewer for the Journal of Addiction Medicine. Currently Dr. Salsitz is the chair of the ASAM REMS ER/LA Opioids committee. Dr. Salsitz is a member of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He is the recipient of the 2014 ASAM Annual AwardDr. Salsitz is a member of the Medical Advisory Panel, for the New York State Office of Alcohol and Substance Abuse Services.

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.   A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego.  Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions.  She previously worked at a large outpatient addiction treatment program serving over 5000 patients.  Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders.  She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction.  During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships.  She completed a fellowship in Addiction Psychiatry at Yale.  During residency and her early faculty years, she founded and led the Yale Global Mental Health Program.  She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry.  She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program. 

    Abigail J. Herron

    DO, DFASAM

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

    Sharon Stancliff

    MD, FAAFP

    Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations. Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.

    Timothy Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency treatment program in Rochester, NY and as detoxification specialist for Syracuse Behavioral Health in Rochester, NY. Tim serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

  • The ASAM Review Course in Addiction Medicine 2017

    Contains 25 Product(s)

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 800 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives:

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2017 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/26/2017, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients 
  • Opioid Prescribing: Safe Practice, Changing Lives (2.5 CME)

    Contains 5 Component(s), Medical Credits Offered

    Review safe prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.

    Horizontal Logo.jpg

    The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 2000 to 2015 more than half a million people died from drug overdoses.
    • 91 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives course addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

    Learners will be able to:

    • Accurately assess patients with pain for consideration of an opioid trial
    • Establish realistic goals for pain management and restoration of function
    • Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
    • Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
    • Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
    • Educate patients about safe storage and disposal of opioids
    • Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician at Mount Sinai Beth Israel, Department of Psychiatry and Behavioral Sciences, since 1983, and is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.  He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.  Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease.  He  lectures frequently and has been published on a variety of addiction medicine topics.

    Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT and PCSS-O mentoring programs. He has co-chaired  the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art Course and  is a reviewer for the Journal of Addiction Medicine. Currently Dr. Salsitz is the chair of the ASAM REMS ER/LA Opioids committee. Dr. Salsitz is a member of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He is the recipient of the 2014 ASAM Annual AwardDr. Salsitz is a member of the Medical Advisory Panel, for the New York State Office of Alcohol and Substance Abuse Services.

    Kirk Moberg

    MD, PhD, FASAM

    Dr. Moberg has served as medical director of three addiction recovery centers, currently the Illinois Institute for Addiction Recovery in Peoria, IL. He also serves as Clinical Professor in the departments of Internal Medicine and Psychiatry & Behavioral Medicine at UICOM. He holds extensive accomplishments in managing healthcare quality and outcomes; implementing performance improvement and project management methods; managing hospital, medical group, and managed care operations. He is certified by the American Board of Internal Medicine, the American Board of Addiction Medicine and the Certifying Commission for Medical Management.

    He is a member of the board of the Illinois Society of Addiction Medicine and the National Rural Association for Alcohol and Drug Abuse, Inc. Dr. Moberg also serves on the Advisory Committee of the Illinois Professional Health Program.

    CME Information and Disclosure Listing

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 2.5 AMA PRA Category 1 Creditsto the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    None

    Catherine Friedman, MD

    None

    Noel Ilogu, MD, MRCP None

    Herbert Malinoff, MD, FACP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    John Tanner, DO, DFASAM

    Reckitt

    Astra Zeneca

    Pfizer

    Alkermes

    Honorarium

    Honorarium

    Honorarium

    Honorarium

    Speaker

    Speaker

    Speaker

    Speaker

    Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Herbert Malinoff, MD, FACP, DFASAM

    None

    Yngvild Olsen, MD, MPH

    None

    Theodore Parran, MD

    None

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, FACEP, DFASAM

    None


    Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin Salsitz, MD, DFASAM

    None

    Kirk Moberg, MD, PhD, FASAMNone

    ASAM CME Committee Reviewers

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jacob Bobrowski, MD, FAAFP

    None

    Anthony H. Dekker, DO, DFASAM

    None

    Acknowledgement

    Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

    RPC Commercial Support Disclosure Statement

    This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

    This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

  • The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar helps build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document, which guides provider decisions about drug testing, as no universal standard exists today.

    image


    This webinar helps build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document, which guides provider decisions about drug testing, as no universal standard exists today. It will allow providers, patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regard to drug testing in clinical addiction medicine. This webinar is primarily intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population.


    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and currently serves on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and niw currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Upon completion of this activity, participants should be able to:
    -Recognize the importance of the guidance needed around drug testing today
    -Identify the fundamental components of drug testing in a clinical setting
    -Summarize the document's recommendations and discuss how they should be used in practice
    -Address common clinical questions around drug testing in a clinical setting

  • Research-Based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse: Being Part of the Solution

    Contains 4 Component(s)

    This activity has been designed to meet the educational needs of clinicians including, physicians, physician assistants, nurse practitioners, nurses, and dentists/oral maxillofacial surgeons, involved in the care of adolescent patients.

    image

    ASAM is part of a collaboration that made this course possible.

    Educational Objectives

    After completing this activity, the participant should be better able to:

    Part 1

    • Describe the prevalence of substance use and prescription drug misuse among adolescents
    • Explain why adolescents are at high risk of developing a substance use disorder and how clinicians can help prevent it
    • Demonstrate strategies to build trust with adolescent patients and ensure confidentiality when addressing substance use and prescription drug misuse
    • Summarize ways to identify substance use and prescription drug misuse in adolescent patients, including determining their level of risk

    Part 2

    • Discuss strategies to address substance use and prescription drug misuse in adolescent patients based on their level of use
    • Summarize when and how to follow up with adolescent patients who use substances or misuse prescription drugs

    Physician Continuing Medical Education

    Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and the National Institute for Drug Abuse. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Continuing Education

    Credit Designation

    This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

    Accreditation Statement  

    Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    American Dental Association CERP Recognition

    This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint sponsorship efforts between Postgraduate Institute for Medicine and the National Institute for Drug Abuse.

    Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.  ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

    Postgraduate Institute for Medicine designates this activity for 1.0 continuing education credit.

    Education Coalition

    This activity was developed by an education Coalition of experts and medical professional organization representatives. The Coalition comprises the following organizations and experts:

    Type of Reviewer: Organization/ Expert Consultant

    Reviewer Name

    California Academy of Family Physicians (CAFP)

    Cynthia Kear, Senior Vice President

    American Society of Addiction Medicine (ASAM)

    Jennifer Butchart, Specialist, Professional Development  
    Penny S. Mills, MBA, Executive Vice President / CEO     
    Arlene C. Deverman, CAE, Chief Learning Officer

    American Osteopathic Association (AOA)

    Stephanie Townsell, Public Health Project Manager

    Marla Kushner, DO

    American Association of Nurse Practitioners (AANP)

    Anne Norman, DNP, APRN, FNP-BC, Associate Vice President of Education

    American Academy of Pediatrics (AAP)

    Renee Jarrett, Manager, Mental Health and Foster Care Initiatives Div of Developmental Pediatrics and Preventive Services

    American Academy of Physician Assistants (AAPA)

    Daniel Pace, Vice President, Education
    Marie-Michele Leger, MPH, PA-C, Director, Clinical Education Sara Evans, PMP, Project Manager, Quality Improvement Initiatives

    American Association of Oral and Maxillofacial Surgeons (AAOMS)

    Vincent DiFabio, DDS

    Consultant

    Samantha Mattiucci, PharmD, CHCP, Director of Medical Education

    Consultant

    Jan Schultz, BSN, MSN, RN, CHCP, Director of Education Outcomes and Accreditation Services

    Consultant

    Dan Alford, MD, Associate Professor of Medicine, Assistant Dean and Program Director of the Addiction Medicine Residency program at Boston University School of Medicine

    Consultant

    Sharon Levy, Director, Adolescent Substance Abuse Program (ASAP)Assistant Professor in Pediatrics,  Boston Children's Hospital

    Consultant

    Jeff Baxter, MD, Assistant Professor Department of Family Medicine and Community Health, University of Massachusetts Medical School

    Consultant

    Marc Fishman, MD

    Consultant

    Carol Havens, MD

    Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The Education Coalition members reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Marc Fishman, MD discloses the following: Consulting Fees: US World Meds; Contracted Research: Media Rez, US World Meds

    Ownership Interest: Maryland Treatment Centers

    The following Education Coalition members have nothing to disclose: Cynthia Kear, Jennifer Butchart, Penny Mills, Arlene Deverman, Stephanie Townsell, Marla Kushner, Anne Norman, Renee Jarrett, Daniel Pace, Marie-Michele Leger, Sara Evans, Vincent DiFabio, Jan Schultz, Dan Alford, Sharon Levy, Jeff Baxter, Marc Fishman, and Carol Havens

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    The following National Institute on Drug Abuse planners and managers, Elisabeth Davis; Carol Krause; Josie Anderson; Jack Stein, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

    The following JBS International, Inc. planners and managers, Candace Baker; Susan Hayashi; Laura Nolan; Bethel Arya; and Veronica Junghahn, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

    For Physicians, Registered Nurses and Dentists, please follow the instructions below:

    PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. Go to CME University at: www.cmeuniversity.com and register or login
    2. Once logged in, click on “Find Post-test/Evaluation by Course” at the top of the page
    3. Type in 11118 (for Part1) or 12614 (for Part 2) in the box; hit enter
    4. Click on the activity title
    5. Complete the online posttest and evaluation and obtain your CME certificate to download and/or print for your files.

    Upon completion of the online posttest and evaluation form, you will have immediate access to a certificate of attendance to print or save for your files. You can save your certificate by selecting the “Save” option on the print screen. 

    For any questions relating to the physician, nursing or dentist accreditation, please contact PIM via:  inquiries@pimed.com

    For Nurse Practitioners follow the instructions below:

    • Visit the AANP’s Website (coming soon) to take the course for AANP credit.

    For Physician Assistants follow the instructions below:

    • Visit the AAPA’s Website to take the course for AAPA credit.

    For Doctors of Osteopathic Medicine follow the instructions below:

          Visit the AOA’s Website (coming soon) to take the course for AOA credit.

    Internet activity

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Board Exam Study Tool (BEST) - 2017

    Contains 3 Component(s), Medical Credits Offered

    Learn from the BEST, the internet-based learning tool that includes study material and competency-based test questions to help prepare examinees in an interactive, engaging, and self-paced format.

    The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format. This online learning tool includes study materials such as slides from the Review Course, chapter overviews from the Principles of Addiction Medicine, a section on definitions, and a bank of practice test questions and answers. The tool offers sustained access to the training material, ability to bookmark pages, highlight text, take notes, track progress through the content, and can be accessed through supported mobile devices and tablets.

    Goals and Objectives

    Upon completion of this education activity, participant should be able to:

    • Differentiate between important terms and definitions in the field of Addiction Medicine.
    • Distill knowledge on key points from the text, the Principles of Addiction Medicine, 5th edition and course slides
    • Appraise addiction patient cases and respond accurately to questions about next steps and treatment options.
    • Employ knowledge gained in the educational sections of the BEST to respond accurately to self-assessment questions.

    Participants of the 2017 ASAM Review Course in Addiction Medicine and other physicians who are preparing for the ABPM Certification Exam in Addiction Medicine.

    Accreditation Council for Continuing Medical Education

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

    ASAM designates this enduring material for a maximum of 12 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    Abigail Herron DO, DFASAM
    Petros Levounis MD, MA, FASAM
    Carla Marienfeld, MD
    Ricardo Restrepo MD, MPH, FASAM
    Edwin Salsitz MD, DFASAM
    Erin Zerbo, MD
    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM
    Jeffrey DeVido MD Marin County Health and Human Services/UCSF Dividend Shareholder
    Paul Earley MD, DFASAM Georgia Professionals Health Program, Inc; Alkermes, Inc; DynamiCare Health, Inc salary; honoraria Medical Director; Principal; VP of Medical Affairs 
    James Finch MD, DFASAM Orexo Pharm honorarium Speaker
    Marc Fishman MD, DFASAM US World Meds; Alkermes; MediaRez travel expenses; honoraria; research support Advisory board; PI; Consultant
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    Leslie Hayes, MD
    Abigail Herron DO, DFASAM
    Petros Levounis MD, MA, FASAM
    Carla Marienfeld MD
    Ricardo Restrepo MD, MPH, FASAM
    Richard Ries MD, DFASAM
    Edwin Salsitz MD, DFASAM
    Sharon Stancliff MD, FASAM
    Timothy Wiegand MD, FACMT, FAACT
    Erin Zerbo, MD
  • Close The Gap: Pathways to the Addiction Medicine Exam

    Contains 3 Component(s), Medical Credits Offered

    Nearly 20.5 million Americans suffer from a substance use disorder (SUD), yet only 1 in 10 people with a substance use disorder (SUD) receive treatment. This treatment gap leaves millions without the proper treatment, expanding the addiction medicine workforce is vital. During this webinar, we will discuss how physicians can become board-certified in Addiction Medicine under the new medical subspecialty.

    The 60-minute webinar will provide insights into current addiction treatment gap and how physicians can close this gap by becoming board-certified in addiction medicine certified through the upcoming American Board of Preventive Medicine addiction medicine exam

    This webinar is targeted toward clinicians, physicians, academicians and other addiction medicine professionals looking to learn more the addiction treatment gap and the new addiction medicine subspecialty under the American Board of Preventive Medicine (ABPM). 

    The purpose of the webinar is to emphasize the need to close the current treatment gap and increase the addiction medicine workforce. There will be a key focus on the new addiction medicine subspecialty and the pathways for certification. There will be a live question and answer session during the webinar to address any concerns and foster conversation around this monumental development in the field. 

    • Addiction medicine specialists
    • Opioid treatment program providers
    • DATA-waived provider
    • Public health management services providers

    Upon completion of this activity, participants will be able to:

    •  Demonstrate the importance of the need for an expanded workforce.  
    •  Describe the different hurdles patients faces when seeking treatment for addiction treatment.
    •  Identify different demographics that are uniquely affected by the treatment gap.
    •  Diagram the different learning methods physicians can take to educate themselves in addiction medicine.
    •  Construct an outline of the different pathways physicians can take to become eligible to sit for the addiction medicine exam.
    •  Identify certain criteria physicians have to uphold in order to become an addiction specialist. 

    ACCME Accreditation Statement The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

     AMA Credit Designation Statement: The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    ASAM 2017-2018 CME Committee Disclosure Information:

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, Chair

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    April 7, 2017 – April 2018